PRNewsWire · ABBV · October 23, 2026

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease

Get the app for more

Explore stock news, insights and company research.